CION Ameerpet
Immunotherapy Cost & Access · Deciding Whether to Spend
Is Immunotherapy Worth the Money? — A Framework for Deciding
There is a real answer to this question, and it is not always yes. What immunotherapy costs is set by the drug and the schedule. What it is likely to do for you is set by your cancer type and its approved indication, your biomarker result, which line of treatment this is, and how well you are day to day - the inputs NCCN and ESMO build their eligibility guidance around. This page puts those two sides next to each other, including the scenarios where the honest answer is no. All cost references here are indicative, as of August 2026.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Answer the benefit question first — Ask what the treatment is expected to do in your situation before you ask the price. Doing it the other way round lets the money decide the medicine.
- Most patients are not candidates — Immunotherapy helps a proportion of patients in defined situations. If your cancer type and biomarker result do not point to it, the cost question never needs answering.
- Fund to the first decision point — Budget for the cycles planned before the first response assessment, not for a vague year. That stretch is the only one anyone can honestly plan.
- Sometimes the answer is no - and that is legitimate — Comfort-focused care is an active medical decision, not a failure. Say plainly if money is the constraint; a treating team can plan around a stated limit.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The two questions, in order
How do you weigh the cost of immunotherapy against the likely benefit?
Answer the benefit question first, separately from the money. Ask your oncologist what immunotherapy is expected to do in your exact situation, how likely that is, and what happens without it. Only then put the cost beside it. Reversing the order lets the price decide the medicine.
Families almost always start with the number. It is the frightening part, so it goes first. But a price is only meaningful once you know what it buys, and for immunotherapy that varies enormously from one patient to the next. The same drug, at the same cost, is a reasonable use of money in one situation and a poor one in another. Five inputs decide which situation you are in - and none of them is the price.
| Input | Why it changes the answer | What to ask your oncologist |
|---|---|---|
| Biomarker result (PD-L1, MSI-H / dMMR, TMB) | Checkpoint inhibitors are approved and expected to work in defined biomarker groups. Outside those groups the expected benefit is much lower and the evidence thinner. | Which biomarker was tested, what my result was, and whether it places me in the group this drug is approved for |
| Cancer type and approved indication | Approval is granted per cancer type and per clinical situation, not for cancer in general. Use outside an approved indication rests on weaker evidence. | Is this an approved indication in India for my cancer, at this stage, in this line of treatment? |
| Line of treatment | What the treatment is expected to offer differs between first-line use and use after other treatments have already failed. | Is this first-line, second-line or later, and what did the tumour board actually recommend? |
| Performance status (ECOG) | How well you are day to day is one of the strongest signals of whether any systemic treatment will help more than it harms. | What is my ECOG score today, and does it still support giving this treatment? |
| Goal of treatment | Treating to control disease and treating for comfort are different goals, and the arithmetic of a costly infusion schedule is different for each. | Is the goal control of the disease, or comfort, symptom relief and time at home? |
Notice what is not on that list: how much the family can raise. That belongs in the conversation too, but as a separate input - stated out loud, not silently pruning the options your oncologist puts in front of you.
Did you know?
The total cost of immunotherapy is not fixed on day one. How long treatment continues is decided by response and tolerance, and the first response assessment usually sits two to three months in. That assessment is the natural point to review the money as well as the scans - which is why families are better off funding to that point than trying to budget a whole year in advance.
The consultation to ask for
What questions should you ask before paying for immunotherapy?
Six. What is this expected to do for me. How likely is that in my situation. What happens if we do not do it. How many cycles before we know. What is the full monthly bill. And what is the honest alternative if we cannot sustain it. Ask them together, and ask for the answers in writing.
- 1
“What is this treatment expected to do for my cancer, specifically?”
Not what immunotherapy does in general. What it is expected to do in your cancer type, at your stage, in this line of treatment.
- 2
“How likely is that, given my biomarker result?”
Your oncologist can place you inside or outside the group the treatment is approved for. That placement matters more to this decision than any number on an estimate.
- 3
“What happens if we do not do this?”
Every option has an alternative, including other systemic treatments, a clinical trial, and supportive care alone. Ask for the comparison, not just the recommendation.
- 4
“How many cycles before we know whether it is working?”
This is the number a family can actually fund. Pay for that stretch properly, then reassess the money alongside the scan.
- 5
“What is the full monthly bill, apart from the drug?”
Day care, pre-cycle bloods, hormone monitoring, review consultations and response-assessment imaging, itemised on separate lines and dated.
- 6
“If we cannot sustain this, what is the honest alternative?”
Money is a legitimate constraint and a common one. A treating team can plan around a stated limit; it cannot plan around cycles quietly skipped later.
Immunotherapy is administered as day care at CION centres, so you come in, are treated and go home the same day. Response-assessment PET-CT is coordinated at partner imaging centres, not owned by CION, and is billed by them - published whole-body rates start at ₹9,999 for analog and ₹14,950 for digital, indicative as of August 2026.
The answer nobody writes down
When is immunotherapy not worth the money?
When the biomarker result and cancer type do not point to it. When you are too unwell for treatment to help more than it harms. When the family can fund two cycles of a six-cycle plan. And when the goal has honestly moved to comfort rather than disease control.
Most pages about immunotherapy cost stop at how to pay. That leaves out the harder half of the decision. There are situations where a family should not spend this money, and knowing them before the first cycle protects savings that may be needed for months of care afterwards.
| Scenario | Why the spend is hard to justify | What to discuss instead |
|---|---|---|
| The biomarker result does not support it | Checkpoint inhibitors are approved for defined biomarker and histology groups. Outside them the expected benefit is much lower. | Whether a different systemic treatment, or a clinical trial, fits your result better |
| Performance status is poor and falling | When someone is spending most of the day in bed, systemic treatment more often adds side effects than good days. NCCN and ESMO build performance status into eligibility for this reason. | Symptom control first, and whether treatment would take away more days than it gives |
| Only part of the course can be funded | A course stopped for money halfway is not half a treatment. It is the full cost of the cycles given, with the decision point never reached. | Funding to the first response assessment, scheme routes, trials, or a different plan altogether |
| The goal has moved to comfort | In advanced disease where the family wants time at home and freedom from symptoms, a demanding infusion and monitoring schedule can work against that goal. | Palliative and supportive care as an active plan, made deliberately rather than by default |
| It is being used off-indication on hope alone | Paying for treatment outside its approved indication, with no biomarker rationale behind it, spends money the family is likely to need later. | Ask what the evidence is, and ask whether a trial exists for your exact situation |
Deciding not to treat is a medical decision, not a failure. It deserves the same consultation, the same second opinion and the same tumour-board review as deciding to go ahead. If cost is what is driving the question, say so in the room - it changes what your team can offer you, and it is a reason nobody in oncology finds surprising.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Decide With the Whole Picture in Front of You
Eligibility, likely benefit and the full indicative cost, reviewed together by a tumour board - before a single rupee is committed.
Affordability is part of the clinical decision
What if we can only afford part of the course?
Say so before the first cycle, not halfway through. A course funded to the first response assessment is a real plan. A course that stops when the money runs out is the full cost of the cycles given, without ever reaching the point where anyone learns whether it was working.
This is the single most expensive mistake families make with immunotherapy, and it is always made with good intentions. The plan is to start now and find the rest later. Sometimes the rest is found. Often it is not, and treatment stops at cycle three of eight - too early for the response assessment to mean anything, too late to have spent the money on something else.
There is a better version of the same conversation. Ask how many cycles are planned before the first assessment and fund that stretch fully. Treat the assessment as a joint checkpoint for the scans and for the budget. If the treatment is doing something and the money can be extended, extend it deliberately. If either answer is no, you stop at a planned point with information, rather than at a random one without it.
What Happens If You Run Out of Money Mid-Treatment? walks through what actually happens when a course has to stop, and what can be salvaged. If you want to understand why the number is so large in the first place, Why Immunotherapy Is So Expensive takes apart the pricing.
Levers that move the price, not the treatment
What can lower the cost without changing the medicine?
Five things, mostly. Scheme cover confirmed before cycle one. An insurance pre-authorisation filed correctly the first time. Whether an approved lower-cost version of the molecule exists. How the dose is calculated and scheduled. And whether a clinical trial fits your diagnosis.
- Confirm scheme cover before you start. Under Telangana's Aarogyasri scheme, certain immunotherapy packages may be covered up to scheme-defined ceilings. Empanelment and package contents change - ask the treating hospital's scheme desk for the current position.
- File the insurance pre-authorisation properly the first time. A large share of refusals are documentation problems rather than policy exclusions. Ask which reports the insurer wants, and check sub-limits and how your policy defines day care.
- Ask whether an approved lower-cost version of the molecule exists. For one molecule a domestically manufactured biosimilar has been available in India since January 2026 at a substantially lower price than the reference product; for others none exists yet. Ask your oncologist and the hospital pharmacy - never a reseller.
- Ask how the dose is worked out. Whether a drug is dosed by body weight or as a fixed dose can change what a cycle costs for the same treatment - see Weight-Based vs Fixed Dosing: Does It Change What You Pay?
- Ask whether a clinical trial fits your diagnosis. Some trials supply the study treatment at no drug cost. Eligibility is strict, enrolment is never promised and no trial treatment can be assumed to work - but it costs nothing to ask whether one exists.
- Get an itemised, dated estimate before cycle one. Drug, day care, monitoring bloods, hormone tests and imaging on separate lines. An estimate without a date is not an estimate.
A note on scheme ceilings. Where a package ceiling applies, it caps what the scheme pays - it does not cap what the treatment costs. Anything above the ceiling, and anything the package does not include, is still your family's to meet. Private policies usually reimburse billed amounts within your sum insured, so there the real constraint is how quickly the policy is exhausted.
Nothing on this page says any scheme or insurer will cover your treatment. Coverage is decided on your individual documents and diagnosis, and the rules change. Confirm your own position directly before you commit to anything.
Transparent costs
Decisions for Healing, Not Billing
We will tell you when a treatment is unlikely to be worth what it costs you. That conversation is free, and it is the one families remember.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Is Immunotherapy Worth It? Your Questions Answered
Is immunotherapy worth the cost?
Sometimes, and not always. It depends on four things that have nothing to do with the price: your cancer type and whether this is an approved indication, your biomarker result, which line of treatment this is, and how well you are day to day. Where those line up, immunotherapy can be a reasonable use of a family's money. Where they do not, the same spend buys very little. Answer the benefit question with your oncologist first, in your own situation, then put the cost beside it. Reversing the order lets the price decide the medicine. All cost figures discussed on this page are indicative, as of August 2026.
How do I know if immunotherapy is likely to help in my case?
Ask your oncologist three direct questions. What is this treatment expected to do for my cancer, specifically. How likely is that in someone with my biomarker result and my line of treatment. And what would happen if I did not have it. Immunotherapy is approved per cancer type and per situation, not for cancer in general, and biomarker testing such as PD-L1, MSI or mismatch repair status is what places you inside or outside the group it is approved for. Most patients in India turn out not to be candidates. That is a normal answer, and it is better to hear it before money is committed.
What questions should I ask before paying for immunotherapy?
Six, in one sitting. What is this expected to do for me. How likely is that in my situation. What happens if we do not do it. How many cycles before the first response assessment tells us whether it is working. What is the full monthly bill, with drug, day care, monitoring bloods and scans on separate lines and a date on the estimate. And what is the honest alternative if the family cannot sustain the course. Ask for the answers in writing. An undated estimate is not an estimate, it is a memory.
When is immunotherapy not worth the money?
Four situations come up repeatedly. When the biomarker result and cancer type do not place you in a group the treatment is approved for. When performance status is poor and falling, so treatment is more likely to take days away than to give them. When the family can fund only part of a planned course, because a course abandoned for money is the full cost of the cycles given without ever reaching the decision point. And when the goal has honestly moved to comfort and time at home. Choosing not to treat is a medical decision, not a failure, and it deserves a proper consultation.
What happens if we start immunotherapy and cannot afford to finish it?
You will have paid for the cycles given, and you may stop before the first response assessment, which is the point where anyone learns whether the treatment was doing anything. That is the worst version of this decision, and it is avoidable. Tell the treating team before the first cycle that money is the constraint, and ask them to plan to the first assessment rather than to a vague year. Cycles that are quietly delayed or skipped to save money can change how the treatment works, so the conversation belongs in the consulting room and belongs there early.
Does Aarogyasri or insurance make immunotherapy affordable?
Sometimes, partly, and never automatically. Under Telangana's Aarogyasri scheme certain immunotherapy packages may be covered up to scheme-defined ceilings, and a ceiling caps what the scheme pays, not what the treatment costs. Empanelment and package contents change, so confirm the current position with the treating hospital's scheme desk. Private policies usually reimburse billed amounts within your sum insured, where sub-limits and how the policy defines day care decide how much of the monitoring is actually paid. Nothing on this page is a coverage guarantee. File the pre-authorisation properly before cycle one, because many refusals are documentation problems rather than exclusions.